Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, Ivanova T, Zhang S, Lee M, Wu J, Ngo A, Manesh S, Tan E, Teh BT, So JB, Goh LK, Boussioutas A, Lim TK, Flotow H, Tan P, Rozen SG. Lei Z, et al. Among authors: guan yk. Gastroenterology. 2013 Sep;145(3):554-65. doi: 10.1053/j.gastro.2013.05.010. Epub 2013 May 14. Gastroenterology. 2013. PMID: 23684942
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
Thura M, Al-Aidaroos AQO, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo R, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q. Thura M, et al. Among authors: guan yk. JCI Insight. 2016 Jun 16;1(9):e87607. doi: 10.1172/jci.insight.87607. JCI Insight. 2016. PMID: 27699276 Free PMC article.
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. Thura M, et al. Among authors: guan yk. Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x. Nat Commun. 2019. PMID: 31171773 Free PMC article.
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. Thura M, et al. Among authors: guan yk. Nat Commun. 2021 Nov 2;12(1):6431. doi: 10.1038/s41467-021-26548-6. Nat Commun. 2021. PMID: 34728638 Free PMC article. No abstract available.
The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia.
Yap YY, Law KB, Sathar J, Lau NS, Goh AS, Chew TK, Lim SM, Menon P, Guan YK, Husin AB, Wong LLL, Chew LP, Salleh S, Goh KY, Leong KW, Tan SM, Ong TC, Lim SH, Toh SG, Han XSY, Edmund SC, Tan JT, Chang KM. Yap YY, et al. Among authors: guan yk. Exp Hematol Oncol. 2018 Dec 17;7:31. doi: 10.1186/s40164-018-0124-7. eCollection 2018. Exp Hematol Oncol. 2018. PMID: 30564475 Free PMC article.
A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
Kuan JW, Su AT, Wong SP, Sim XY, Toh SG, Ong TC, Rajasuriarr JS, Lim SH, Guan YK, Liew HK, Liew PK, Tan JT, Kori AN, Cheng YY, Tan SM, Chang KM. Kuan JW, et al. Among authors: guan yk. Transfus Apher Sci. 2015 Oct;53(2):196-204. doi: 10.1016/j.transci.2015.03.017. Epub 2015 Mar 30. Transfus Apher Sci. 2015. PMID: 25910537 Clinical Trial.
13 results